The combination of ticarcillin and clavulanic acid (Timentin) was used in a non-randomized open study in 30 patients with lower respiratory tract infection to assess the clinical efficacy and safety of the drug. The clinical diagnosis were:
pneumonia
(26), lung abscess (2), chronic bronchitis (1), and acute exacerbation of chronic obstructive pulmonary disease (1). Timentin 3.2g were administered every 6 or 8 hours for a mean duration of 10.6 days (range 3~20 days). Timentin was clinically
effective
treatment in 23 (79%) of 29 evaluable patients. The isolated pathogens were P. aeruginosa (7).K. pneumoniae (3), S. pneumoniae (3), S. aureus (2), E. aerogenes (2) and other organisms (5).Four patients with infection due to P. aeruginosa were
failed.
Infection due to other organisms except P. aeruginosa were 14 cases and showed high cure rate of 86%(12/14). Adverse effects were reported from 3 patients: one drug fever, one urticaria and one mild elevation of transaminases.
This open study shows Timentin to be a safe and effective antibiotic for the treatment of the lower respiratory tract infection.
|